RESEARCH TRIANGLE PARK, N.C.– Aperio Clinical Outcomes, a prominent data focused clinical research organization (CRO), appoints Eric Ross as Chief Commercial Officer, as the company adds additional infrastructure to support continued growth. Mr. Ross has served as Aperio’s VP, Business Development for the past two years as the company increased and expanded their market presence, revenues, and client base.
Ross has over 18 years of experience in life sciences, including current oversight of Aperio’s business development, marketing, budgets and proposals, and contracts teams. Prior to his current role, Ross spent eight years leading Business Development growth as an executive in the CRO industry at Medsource, Chiltern and Ockham Oncology through their successful acquisitions. Previously, Ross served in various Director and Manager Operations roles at Almac and etrials Worldwide where he held senior operations positions in Project and Product Management.
According to Faye Woolf, the Founder and CEO of Aperio, “We are delighted to have Eric Ross expand his role here at Aperio taking over leadership of commercial activities. His deep understanding of the market and embrace of Aperio’s culture have helped fuel our growth as a data focused CRO during his time with the organization. Leveraging Eric’s strong principles, combined with his extensive background in operations and acumen in Business Development, will empower him to strategically position Aperio for growth. This experience across various segments of the clinical trial industry allows him to be uniquely attuned to the challenges Aperio’s small and mid-size biotech clients face and the benefits of expert database design and advanced data analytics allowing our sponsors 24/7 access to their clinical trial data enabling proactive, informed, and intelligent decisions.”
“I am truly excited about the opportunity to take on this expanded role,” said Mr. Ross. “Aperio’s values and its dedication to quality, transparency, and customer-centricity closely resonate with my own. I firmly believe that building strong relationships and fostering trust form the foundation for successful collaborations between biotech companies and CROs. I am eager to utilize my extensive industry experience and broad network within the biotech sector to propel Aperio’s strategic growth.”
